Aspen Alert’s Post

Everything you missed in #Pharma & #Biotech 🦠🔬 ✅ Approvals FDA approves Amneal Pharmaceuticals’ Crexont, an extended-release formulation of levodopa-carbidopa for Parkinson's disease Servier's vorasidenib receives FDA approval for treating a specific type of brain tumor called IDH1 or IDH2-mutant glioma, marking the first USA approval for this condition FDA rejects Lykos Therapeutics' application for MDMA-assisted therapy for PTSD, requesting additional studies to assess safety and efficacy 💸 Deals Exscientia and Recursion, two leading AI-driven biotech firms, to merge in a deal valued at $688 million, combining strengths in AI and drug discovery Sangamo Therapeutics, Inc. Therapeutics secures $1.9 billion deal with Genentech, receiving $50 million upfront and exclusive rights to develop genomic neurodegenerative therapies Daiichi Sankyo and Merck enter global development and commercialization Agreement for MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager Merck to acquire an investigational bispecific antibody for B-cell-associated diseases from Curon Biopharmaceutical for $700 million upfront, enhancing pipeline in autoimmune and oncology Denmark's Pharmacosmos to acquire commercial-stage oncology company G1 Therapeutics, Inc. for $405 million Roche licenses technology from Sangamo Therapeutics, Inc. Therapeutics through its Genentech arm to create genomic medicines for select neurodegenerative diseases L'Oréal acquires 10% stake in dermatology group Galderma 📈 Access The GBA announces amendments to its procedural rules to require early benefit assessments for all reimbursable drugs, including those without competitors, and allows use of off-label treatments as appropriate comparator therapies (ACTs) based on the actual care situation and recognized medical standards ✳️ Other BioMarin Pharmaceutical Inc. to focus its Roctavian (hemophilia gene therapy) plans on Germany and Italy (in addition to the USA) due to regulatory and logistical challenges 👉 What’s your favorite industry news? #pharma #biotech #pulsenews #curiousminds #techbio Hannah Kurth Patricia Machado Tamsin Lacourte Alexandra SILVAIN

Exciting News! Pheiron has entered a strategic collaboration with Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Co., Ltd to accelerate the discovery and development of RNA-based therapeutics with evidence from large human populations generated through PheironGPS. This partnership will bring advanced human evidence to Ribo’s focus on cardiometabolic diseases, helping to: ▶ Prioritize therapeutic targets ▶ Pinpoint causal disease mechanisms ▶ Optimize patient stratification for clinical development We will work closely with Ribo’s stellar scientists to enhance the probability of success in developing next-generation therapies for unmet medical needs. Stay tuned for more updates on this exciting journey! More information: https://lnkd.in/eGPyGYjY https://lnkd.in/eC4vdj27 PheironGPS: https://lnkd.in/e7q52qWP #GeneticEvidence #PopulationCohorts #Phenotyping #RNATherapeutics #AIbiomarker #AIinDrugDevelopment #CardiometabolicDiseases #PheironGPS #Biotech #PharmaInnovation

More hope is on the horizon for the future of Alzheimer’s disease with the announcement that Novo Holdings have led a $100 million series C funding round for Asceneuron SA, a Swiss-based clinical stage biotechnology company. The funding is backed by a renowned syndicate of investors including EQT Life Sciences – LSP Dementia Fund, GSK Equities Investments, OrbiMed, SR One, Sofinnova Partners, M Ventures and Johnson & Johnson Innovation – JJDC. Asceneuron are developing an oral small molecule drug, ASN51, that targets tau protein aggregation through the inhibition of OGA (O-GlcNAcase). The aim of ASN51 is to prevent tau protein aggregation to slow the progression of Alzheimer’s disease, with the oral formulation providing greater convenience to patients compared to existing intravenous treatments. Following phase 1 trials showing that ASN51 is taken up by the central nervous system and has an effect on OGA, the new funding will be used to advance the drug into phase 2 trials. I’m looking forward to seeing the outcomes of the phase 2 study as Asceneuron plan to initiate the clinical trials later this year. #clinicalresearch #clinicalstudy #clinicaltrials #alzheimersresearch #biotechnology #asceneuron #asn51 #pharmaceutical

Biopharma represents a dynamic sector that offers targeted and precise treatments for complex diseases at a molecular level, often with fewer side effects compared to conventional drugs 🌟🔬 Unlike traditional #pharmaceuticals, which are typically synthesised chemically, #biopharma products are derived from living organisms such as cells, tissues, or proteins. This involves a significant amount of #technology, #innovation, and of course #investment💡💰 On that note, we have curated a list of 10 promising biopharma startups in Europe that are at the forefront of this innovation. These companies, all founded between 2019 and 2024, are advancing scientific knowledge and developing groundbreaking treatments that have the potential to transform healthcare globally. Accession Therapeutics Limited,  Adendra Therapeutics, Cellcolabs, Multiomic Health, Muna Therapeutics Neurosterix Nuage Therapeutics Ochre Bio, Quercis Pharma, Cimeio Therapeutics https://lnkd.in/dVeUhW8p

🚀 Third Arc Bio Launches with $165M Series A to Revolutionise Biologics! 🧬💉 Third Arc Bio has successfully secured an oversubscribed $165 million Series A financing! This significant investment will fuel the development of superior biologics targeting solid tumors and inflammatory & immunology (II) diseases. 🔹 Key Highlights: -Strong Investor Support: The Series A round was led by premier biotech investors, underscoring confidence in Third Arc Bio's innovative approach. -Focus on Breakthrough Therapies: Third Arc Bio aims to advance biologics that offer enhanced efficacy and safety profiles for patients suffering from hard-to-treat conditions. -Expert Leadership: The company is led by a team of seasoned professionals with a proven track record in biotech and drug development. 🗣 Quote from the CEO: "We are excited to embark on this journey to deliver next-generation biologics that address significant unmet medical needs. Our team's expertise and the strong support from our investors will be crucial in bringing these transformative therapies to patients." — Peter Lebowitz 🌐 About Third Arc Bio: Third Arc Bio is committed to pushing the boundaries of biologics to improve patient outcomes in oncology and immunology. The company's cutting-edge research and development efforts are poised to make a substantial impact in the biotech industry. #Biotech #HealthcareInnovation #SeriesAFunding #ThirdArcBio #Oncology #Immunology #Biologics #Investment #Pharma #MedicalResearch #InnovationInMedicine

📢 Exciting New Thought Leadership Alert ‼ Dive into the future of bio-conjugates for therapeutics with our latest thought leadership article on Antibody-Oligonucleotide Conjugates Clinical Manufacturing by Muctarr Sesay, Natalia Bourguignon, Ph.D. & Hyung-il Lee. 💡 In this article, we explore the paradigm shift in manufacturing processes, paving the way for groundbreaking advancements in therapeutic development. Key highlights include: 🔬 Unveiling the synergistic potential of antibody-oligonucleotide conjugates. 🛠️ Revolutionary manufacturing techniques reshaping clinical production. 💊 Implications for the future of precision medicine and targeted therapies. Join the conversation and stay ahead of the curve in the evolving landscape of biopharmaceuticals. Click the link below to read the full article now! 👇 https://lnkd.in/gjpwMgHx #CDMO #BioConjugates #Therapeutics #Innovation #Biopharma #ThoughtLeadership"

Take a look at our Subject Matter Experts (SME) AOC article ‼ 👇

The Life Sciences industry continues to advance with groundbreaking progress and key achievements this week. Here are some of the most remarkable updates: Akero Therapeutics has dosed its first patient in the Phase 3 SYNCHRONY Outcomes Study of Efruxifermin for patients with compensated cirrhosis due to MASH. CytomX Therapeutics initiated dosing of its first patient with CX-801, a dually-masked interferon-alpha 2b PROBODY, in a Phase 1 study targeting patients with solid tumors. Rezolute, Inc. received FDA clearance to lift partial clinical holds on RZ358 for the treatment of congenital hyperinsulinism, allowing U.S. inclusion in its ongoing Phase 3 study. Terns Pharmaceuticals reported positive Phase 1 clinical trial results for TERN-601, a once-daily oral GLP-1R agonist aimed at treating obesity. Culture Biosciences announced a collaboration with Google Cloud to revolutionize bioprocess development. Innovent Biologics delivered an oral presentation on Phase 1 clinical data of IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, in advanced non-small cell lung cancer at the 2024 WCLC. Inflammatix, Inc. secured $57 million to advance its novel diagnostic for patients with suspected infections or sepsis. These developments reflect the relentless drive for innovation within the life sciences sector. Stay connected as we continue to monitor the latest advancements and breakthroughs in this dynamic industry! #LifeScience #Biotech #HealthTech #Innovation #AI #Healthcare #ClinicalTrials #FDAApproval #Pharma #HealthcareInnovation #MedTech #Biopharma #DrugDevelopment #ResearchAndDevelopment #BiotechNews #Pharmaceuticals #SFBay #DrugDiscovery #Genomics

We are delighted to provide our first business update since delisting from AIM earlier this year and continue our journey from a discovery to an immuno-inflammation therapeutics company. We're making important progress with our small molecule drug discovery portfolio in immuno-inflammatory diseases, focusing on areas with significant unmet need and commercial potential. Our lead oral a4b7 integrin inhibitor for inflammatory bowel disease is nearing pre-clinical candidate selection, with planning for IND-enabling studies well underway. And we announce two new pipeline programmes which are progressing towards Lead Optimisation, with first-in-class and best-in-class potential. Elsewhere we are applying our PatientSeek platform to define a genetic fingerprint as a predictive biomarker for a4b7 response that will allow us to specifically design our pivotal clinical trials for success. Read more here:  https://lnkd.in/dbBTEKZx #C4XD #immuno_inflammation #biotech #innovation 

The Life Sciences industry continues to advance with groundbreaking progress and key achievements this week. Here are some of the most remarkable updates: Caribou Biosciences has received FDA Fast Track Designations for CB-010 in Refractory SLE and CB-012 in Relapsed or Refractory AML. Denali Therapeutics had a successful meeting with the FDA and plans to file for Accelerated Approval of Tividenofusp Alfa (DNL310) for the treatment of MPS II (Hunter Syndrome). Circle Pharma, Inc. Pharma closed a $90 million Series D financing to advance its innovative oral macrocycle therapies. ThinkCyte secured $32 million in Series C funding to drive the global expansion of its VisionSort technology. Innovent Biologics received Fast Track Designation from the U.S. FDA for IBI363, a PD-1/IL-2α bispecific antibody fusion protein, as monotherapy for advanced melanoma. Synthekine was granted FDA Fast Track Designation for its CD19 CAR-T and Orthogonal IL-2 investigational therapy, SYNCAR-001 + STK-009, for the treatment of lupus without lymphodepletion. Arsenal Biosciences, Inc. raised $325 million to advance its programmable cell therapy programs through clinical development. Sonoma Biotherapeutics received a $45 million milestone payment from Regeneron under their ongoing collaboration. Abdera Therapeutics received FDA Orphan Drug Designation for ABD-147 for the treatment of neuroendocrine carcinoma. Switch Bioworks raised $17 million in Series Seed financing to bring its new biological fertilizer technology to the field. OrsoBio completed an oversubscribed $67 million Series B financing to accelerate the development of its mitochondrial protonophore portfolio targeting obesity and associated disorders. These developments reflect the relentless drive for innovation within the life sciences sector. Stay connected as we continue to monitor the latest advancements and breakthroughs in this dynamic industry! #LifeScience #Biotech #HealthTech #Innovation #AI #Healthcare #ClinicalTrials #FDAApproval #Pharma #HealthcareInnovation #MedTech #Biopharma #DrugDevelopment #ResearchAndDevelopment #BiotechNews #Pharmaceuticals #SFBay #BiotechNews #DrugDiscovery #Genomics